Cargando…
Using antibodies against P2Y and P2X receptors in purinergic signaling research
The broad expression pattern of the G protein-coupled P2Y receptors has demonstrated that these receptors are fundamental determinants in many physiological responses, including neuromodulation, vasodilation, inflammation, and cell migration. P2Y receptors couple either G(q) or G(i) upon activation,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265709/ https://www.ncbi.nlm.nih.gov/pubmed/22086554 http://dx.doi.org/10.1007/s11302-011-9278-z |
_version_ | 1782222119174668288 |
---|---|
author | Brass, Dovrat Grably, Melanie R. Bronstein-Sitton, Noemi Gohar, Ofra Meir, Alon |
author_facet | Brass, Dovrat Grably, Melanie R. Bronstein-Sitton, Noemi Gohar, Ofra Meir, Alon |
author_sort | Brass, Dovrat |
collection | PubMed |
description | The broad expression pattern of the G protein-coupled P2Y receptors has demonstrated that these receptors are fundamental determinants in many physiological responses, including neuromodulation, vasodilation, inflammation, and cell migration. P2Y receptors couple either G(q) or G(i) upon activation, thereby activating different signaling pathways. Ionotropic ATP (P2X) receptors bind extracellular nucleotides, a signal which is transduced within the P2X protein complex into a cation channel opening, which usually leads to intracellular calcium concentration elevation. As such, this family of proteins initiates or shapes several cellular processes including synaptic transmission, gene expression, proliferation, migration, and apoptosis. The ever-growing range of applications for antibodies in the last 30 years attests to their major role in medicine and biological research. Antibodies have been used as therapeutic tools in cancer and inflammatory diseases, as diagnostic reagents (flow cytometry, ELISA, and immunohistochemistry, to name a few applications), and in widespread use in biological research, including Western blot, immunoprecipitation, and ELISPOT. In this article, we will showcase several of the advances that scientists around the world have achieved using the line of antibodies developed at Alomone Labs for P2Y and P2X receptors. |
format | Online Article Text |
id | pubmed-3265709 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-32657092012-02-21 Using antibodies against P2Y and P2X receptors in purinergic signaling research Brass, Dovrat Grably, Melanie R. Bronstein-Sitton, Noemi Gohar, Ofra Meir, Alon Purinergic Signal Original Article The broad expression pattern of the G protein-coupled P2Y receptors has demonstrated that these receptors are fundamental determinants in many physiological responses, including neuromodulation, vasodilation, inflammation, and cell migration. P2Y receptors couple either G(q) or G(i) upon activation, thereby activating different signaling pathways. Ionotropic ATP (P2X) receptors bind extracellular nucleotides, a signal which is transduced within the P2X protein complex into a cation channel opening, which usually leads to intracellular calcium concentration elevation. As such, this family of proteins initiates or shapes several cellular processes including synaptic transmission, gene expression, proliferation, migration, and apoptosis. The ever-growing range of applications for antibodies in the last 30 years attests to their major role in medicine and biological research. Antibodies have been used as therapeutic tools in cancer and inflammatory diseases, as diagnostic reagents (flow cytometry, ELISA, and immunohistochemistry, to name a few applications), and in widespread use in biological research, including Western blot, immunoprecipitation, and ELISPOT. In this article, we will showcase several of the advances that scientists around the world have achieved using the line of antibodies developed at Alomone Labs for P2Y and P2X receptors. Springer Netherlands 2011-11-16 2012-02 /pmc/articles/PMC3265709/ /pubmed/22086554 http://dx.doi.org/10.1007/s11302-011-9278-z Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Original Article Brass, Dovrat Grably, Melanie R. Bronstein-Sitton, Noemi Gohar, Ofra Meir, Alon Using antibodies against P2Y and P2X receptors in purinergic signaling research |
title | Using antibodies against P2Y and P2X receptors in purinergic signaling research |
title_full | Using antibodies against P2Y and P2X receptors in purinergic signaling research |
title_fullStr | Using antibodies against P2Y and P2X receptors in purinergic signaling research |
title_full_unstemmed | Using antibodies against P2Y and P2X receptors in purinergic signaling research |
title_short | Using antibodies against P2Y and P2X receptors in purinergic signaling research |
title_sort | using antibodies against p2y and p2x receptors in purinergic signaling research |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265709/ https://www.ncbi.nlm.nih.gov/pubmed/22086554 http://dx.doi.org/10.1007/s11302-011-9278-z |
work_keys_str_mv | AT brassdovrat usingantibodiesagainstp2yandp2xreceptorsinpurinergicsignalingresearch AT grablymelanier usingantibodiesagainstp2yandp2xreceptorsinpurinergicsignalingresearch AT bronsteinsittonnoemi usingantibodiesagainstp2yandp2xreceptorsinpurinergicsignalingresearch AT goharofra usingantibodiesagainstp2yandp2xreceptorsinpurinergicsignalingresearch AT meiralon usingantibodiesagainstp2yandp2xreceptorsinpurinergicsignalingresearch |